Cystic Fibrosis sufferer Jillian McNulty (from her hospital bed) discusses the withdrawal of funding for the drug Kalydeco. Jillian is among 120 people in Ireland who require the medication
The National Centre for Pharmacoeconomics this week ruled the drug was “not cost effective””.
Kalydeco is described by CF Ireland as “one of the most important advances in the treatment of cystic fibrosis since the discovery of the CF gene” [in 1989]. It helps sufferers “breathe more easily, gain weight and resulted in significant improvements in quality of life.”